Liver fibrosis • biomarker • drug development
The prevalence of fatty liver disease mirrors the global burden of the metabolic syndrome, while numbers alarmingly continuing to rise. Understanding the underlying disease mechanisms with cutting-edge human models, refining targeted biomarker analysis, and discovering innovative drug targets are key for the development of effective therapies.
Program:
10.25 – 10.30 Welcome
Life Science Net Düsseldorf, BioCologne
10.30 – 10.40 Introduction
Prof. Dr. Juergen Eckel, CEO, CMR CureDiab | Metabolic Research GmbH, Düsseldorf
10.40 – 11.00 Hepatic energy metabolism in steatotic liver diseases: mechanisms and therapeutic targets
Dr. Bedair Dewidar, Postdoctoral Researcher, German Diabetes Center, Düsseldorf
11.00 – 11.20 Immunometabolic profiles of tissue-resident and monocyte-derived hepatic macrophage subsets during MASLD development
Dr. Bruno Guigas, Associate Professor, Leiden University Medical Center, Leiden, NL
11.20 – 11.40 The development of a liver-chip for detection of drug-induced liver injury and fatty liver disease
Dr. Lorna Ewart, CSO, Emulate Inc. Boston, US
11.40 – 12.00 FibroPaths liver: combinatorial approach of in silico, 2D and 3D ex vivo methods for the identification of novel therapeutic targets in human liver diseases
PD. Dr. Jan Fiedler, Group Leader Molecular Biomarkers for Disease Modelling, Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover
Lunch Break
13.00 – 13.20 The use of artificial intelligence for the analysis of histological imaging data
Dr. Tobias Seraphin, Clinical Scientist & Resident, Department of Gastroenterology, Hepatology, and Infectious Diseases, Düsseldorf University Hospital, Düsseldorf
13.20 – 13.40 Dissecting Fibrotic Pathways: the extra-cellular matrix as a driver and target
Prof. Dr. Gerhard Sengle, Group Leader Department of Pediatric and Adolescent Medicine, University Hospital, Center for Molecular Medicine Cologne
13.40 – 14.00 From bench to bedside and back to the future: lifecycle of pre-clinical and clinical liver fibrosis biomarkers
Dr. Dimitar Tasev, CSO, GBS, Leiden
Coffee Break
14.20 – 14.40 Role of Sema3A in early MASLD
Prof. Dr. Eckhard Lammert, Head of Institute of Metabolic Physiology, Heinrich Heine University, Düsseldorf
14.40 – 15.00 New MASLD drugs
Prof. Dr. Juergen Eckel, CEO, CMR CureDiab Metabolic Research, Düsseldorf
15.00 Networking